Management Updates 2007 Guidance
Reflecting the results for the first nine months of the year and the integration of Ultrascan, Digirad anticipates consolidated revenues for 2007 in the range of $74.5 million to $75.5 million, consisting of DIS revenue between $53.0 million and $53.5 million and product revenue between $21.5 million and $22.0 million; and consolidated net results for 2007 ranging from breakeven to a net loss of $1.0 million, including estimated stock-based compensation expense of $1.1 million. Results for 2006 include $2.0 million in revenue from sales of stress agents. Digirad discontinued sales of stress agents in June 2006.
Conference Call Information
Digirad has scheduled a conference call at 11:00 a.m. EDT today. A simultaneous webcast of the call may be accessed online from the Events & Presentations link on the Investor Relations page at http://www.digirad.com; an archived replay of the webcast will be available within 15 minutes of the end of the conference call. A telephone replay of the call will be available at (800) 406-7325 or (303) 590-3030, conference ID #3793192 from approximately 2 p.m. EDT. The telephone replay will be available until 11:59 pm EDT on October 27, 2007.
Digirad Corporation provides diagnostic nuclear and ultrasound imaging
systems and services to physicians' offices, hospitals and other medical
services providers for cardiac, vascular, and general imaging applications.
Digirad's Cardius XPO line of nuclear imaging cameras use patented
solid-state technology and unique multi (single, dual, triple) head design
for superior performance and advanced features for sharper digital images,
faster processing, compact size, lighter weight for portability, ability to
handle patients up to 500 pounds, and improved patient comfort compared to
|SOURCE Digirad Corporation|
Copyright©2007 PR Newswire.
All rights reserved